Tadalafil Market Report 2026

The tadalafil market size has grown rapidly in recent years. It will grow from $5.53 billion in 2025 to $6.22 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to rising prevalence of erectile dysfunction, increasing diagnosis of pulmonary arterial hypertension, wider availability of branded tadalafil, expansion of retail pharmacy networks, growing physician awareness of pde5 inhibitors.

The tadalafil market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing aging male population, rising acceptance of online prescription platforms, growing focus on chronic disease management, expansion of combination therapy research, increasing access to affordable generic medications. Major trends in the forecast period include increasing adoption of generic tadalafil formulations, rising demand for long-acting pde5 inhibitors, expansion of online pharmacy distribution, growing focus on patient-centric dosing options, improved manufacturing efficiency for oral solid dosage.

The rising prevalence of erectile dysfunction is expected to drive the growth of the tadalafil market in the coming years. Erectile dysfunction (ED) is a medical condition characterized by the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. The increase in ED prevalence is largely influenced by factors such as an aging population, chronic health conditions, unhealthy lifestyle choices, psychological stress, and side effects of certain medications. Tadalafil treats erectile dysfunction by relaxing smooth muscles in the penile blood vessels, improving blood flow, and enabling the achievement and maintenance of an erection during sexual stimulation. For example, in February 2024, according to a report from the National Library of Medicine, a US-based branch of the National Institutes of Health (NIH), the prevalence of ED measured using IIEF-5 scores was 24.2% across the general population, rising significantly with age - affecting 52.2% of individuals aged 75 and older and 48% of those aged 65-74. Therefore, the growing prevalence of erectile dysfunction is boosting demand for tadalafil.

Key companies in the tadalafil market are focusing on innovative formulations, such as combination therapies, to improve treatment efficacy, enhance patient compliance, and expand market share in the management of erectile dysfunction and pulmonary arterial hypertension. Combination therapy involves using two or more medications or treatments simultaneously to enhance therapeutic outcomes, improve efficacy, and address multiple aspects of a condition. For instance, in March 2024, Johnson & Johnson, a US-based healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved OPSYNVI, a single-tablet therapy combining macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. This therapy is indicated for the chronic management of pulmonary arterial hypertension (PAH) (WHO Group I) in adult patients classified as WHO functional class II-III. OPSYNVI is suitable for both treatment-naïve patients and those currently on ERA, PDE5 inhibitors, or both, offering a streamlined option for patients stabilized on separate doses of macitentan 10 mg and tadalafil 40 mg (20 mg × 2).

In February 2024, Zuellig Pharma Holdings Ltd., a Singapore-based healthcare solutions company, acquired Cialis (tadalafil) and Alimta (pemetrexed) from Eli Lilly and Company for an undisclosed amount. This acquisition enables Zuellig Pharma to expand its pharmaceutical portfolio, strengthen its regional market presence, and better meet growing demand for treatments for erectile dysfunction (Cialis) and cancer (Alimta) across its operational areas. Eli Lilly and Company is a US-based manufacturer of tadalafil-based therapies for erectile dysfunction and pulmonary arterial hypertension.

Major companies operating in the tadalafil market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Jubilant Pharma Limited, Jiangsu Lianhuan Pharmaceutical Co. Ltd., Alembic Pharmaceuticals Limited, Polpharma SA, SMS Pharmaceuticals Limited, Camber Pharmaceuticals Inc., Century Pharmaceuticals Limited, Rakshit Drugs Private Limited, Ami Lifesciences Private Limited, Hangzhou Longshine Bio-Tech Co. Ltd., Dolphin Pharmaceuticals.

North America was the largest region in the tadalafil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tadalafil market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tadalafil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tadalafil market by increasing the cost of imported active pharmaceutical ingredients, excipients, and specialized manufacturing equipment used in tablet and oral suspension production. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on API imports from Asia-Pacific regions such as India and China. These tariffs are raising production costs and placing pressure on pricing strategies for generic and branded tadalafil products. However, they are also encouraging local API manufacturing, regional supplier diversification, and increased investments in domestic pharmaceutical production capabilities.

The tadalafil market research report is one of a series of new reports that provides tadalafil market statistics, including tadalafil industry global market size, regional shares, competitors with a tadalafil market share, detailed tadalafil market segments, market trends and opportunities, and any further data you may need to thrive in the tadalafil industry. This tadalafil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor primarily used to treat erectile dysfunction and pulmonary arterial hypertension. It works by relaxing blood vessels, enhancing blood flow to targeted areas, and helping manage these conditions effectively.

The main product types of tadalafil include tablets and oral suspensions. Tadalafil tablets are solid oral medications that provide accurate dosing, are convenient for patients, and are widely prescribed for conditions like erectile dysfunction due to their effectiveness and ease of use. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Tadalafil is used for various applications, including erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.

The tadalafil market consists of sales of injectable formulations, extended-release formulations, and topical formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.